Contact
searchSearch
HMP Global
Login

Psychedelics Topic Center

Cape Cod Symposium Speakers
Overcoming Perception Barriers and Promoting Safe Access to Psychedelics
09/05/2024
Cape Cod Symposium faculty members Raghu Appasani, MD, PC, Gaetano Vaccaro, PhD, CSAT, and Kaci Hohmann, JD, discuss the barriers and opportunities of psychedelic therapy in conventional psychiatric medicine and addiction recovery
Cape Cod Symposium faculty members Raghu Appasani, MD, PC, Gaetano Vaccaro, PhD, CSAT, and Kaci Hohmann, JD, discuss the barriers and opportunities of psychedelic therapy in conventional psychiatric medicine and addiction recovery
Cape Cod Symposium faculty...
09/05/2024
Psychiatry & Behavioral Health
From Psychiatry & Behavioral Health
Cape Cod Symposium Speakers
Q&As
Exploring the Therapeutic Potential of Psychedelic Treatments in Psychiatry
09/05/2024
Cape Cod Symposium faculty members Raghu Appasani, MD, PC, Gaetano Vaccaro, PhD, CSAT, and Kaci Hohmann, JD, explore the therapeutic benefits of psychedelics, how psychedelics function as adjunctive therapies, and key legal considerations.
Cape Cod Symposium faculty members Raghu Appasani, MD, PC, Gaetano Vaccaro, PhD, CSAT, and Kaci Hohmann, JD, explore the therapeutic benefits of psychedelics, how psychedelics function as adjunctive therapies, and key legal considerations.
Cape Cod Symposium faculty...
09/05/2024
Psychiatry & Behavioral Health
From Psychiatry & Behavioral Health
fda building sign
News
FDA Rejection of MDMA-Assisted Therapy for PTSD Divides Psychedelic Stakeholders
08/16/2024
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug...
08/16/2024
Psych Congress Network
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
News
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
07/24/2024
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with...
07/24/2024
Psych Congress Network
andrew penn
Videos
Decoding the FDA Committee's Decision to Reject MDMA-Assisted Therapy: Part 2
07/01/2024
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP,...
07/01/2024
Psych Congress Network
andrew penn
Videos
Decoding the FDA Committee's Decision to Reject MDMA-Assisted Therapy With Andrew Penn, MS, PMHNP
06/21/2024
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP,...
06/21/2024
Psych Congress Network
FDA
News
FDA Advisory Committee Rejects First MDMA Treatment for PTSD
06/06/2024
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an...
06/06/2024
Psych Congress Network
ketamine brain image
News
Study Findings Support Esketamine and Psilocybin as Effective TRD Treatments
05/14/2024
To address the challenges and “inadequate outcomes” with monoamine-based therapies, a Toronto-based research team investigated novel alternatives for TRD.
To address the challenges and “inadequate outcomes” with monoamine-based therapies, a Toronto-based research team investigated novel alternatives for TRD.
To address the challenges and...
05/14/2024
Psych Congress Network
News
CPT III Codes for Psychedelic-Assisted Therapies Take Effect
01/05/2024
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went...
01/05/2024
Psych Congress Network
News
MAPS PBC Submits New Drug Application for MDMA-Assisted Therapy for PTSD
12/12/2023
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit...
12/12/2023
Psych Congress Network
News
Use of Psilocbyin in Bipolar II Treatment Clinical Trial Produces Strong Results
12/12/2023
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by...
12/12/2023
Psych Congress Network

News Articles

fda building sign
News
FDA Rejection of MDMA-Assisted Therapy for PTSD Divides Psychedelic Stakeholders
08/16/2024
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug...
08/16/2024
Psych Congress Network
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
News
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
07/24/2024
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with...
07/24/2024
Psych Congress Network
FDA
News
FDA Advisory Committee Rejects First MDMA Treatment for PTSD
06/06/2024
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an...
06/06/2024
Psych Congress Network
ketamine brain image
News
Study Findings Support Esketamine and Psilocybin as Effective TRD Treatments
05/14/2024
To address the challenges and “inadequate outcomes” with monoamine-based therapies, a Toronto-based research team investigated novel alternatives for TRD.
To address the challenges and “inadequate outcomes” with monoamine-based therapies, a Toronto-based research team investigated novel alternatives for TRD.
To address the challenges and...
05/14/2024
Psych Congress Network
News
CPT III Codes for Psychedelic-Assisted Therapies Take Effect
01/05/2024
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went...
01/05/2024
Psych Congress Network
News
MAPS PBC Submits New Drug Application for MDMA-Assisted Therapy for PTSD
12/12/2023
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit...
12/12/2023
Psych Congress Network
News
Use of Psilocbyin in Bipolar II Treatment Clinical Trial Produces Strong Results
12/12/2023
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by...
12/12/2023
Psych Congress Network
News
Microdosing Associated With Increased Mindfulness, Lower Neuroticism in ADHD Patients
11/28/2023
A study conducted by researchers in the Netherlands has found that microdosing psychedelics for 4 weeks induced an increase in mindfulness and a decrease in neuroticism among adults diagnosed with attention-deficit/hyperactivity disorder...
A study conducted by researchers in the Netherlands has found that microdosing psychedelics for 4 weeks induced an increase in mindfulness and a decrease in neuroticism among adults diagnosed with attention-deficit/hyperactivity disorder...
A study conducted by researchers...
11/28/2023
Psych Congress Network
News
Compass Pathways Initiates Phase 3 Study of Psilocybin for Treatment-Resistant Depression
11/27/2023
Compass Pathways, which recently opened a new research center in London, has begun a multi-site study of investigational psilocybin treatment of treatment-resistant depression.
Compass Pathways, which recently opened a new research center in London, has begun a multi-site study of investigational psilocybin treatment of treatment-resistant depression.
Compass Pathways, which recently...
11/27/2023
Psych Congress Network
Christopher Nicholas, PhD
News
Psychedelics Show Potential to Improve SUD Treatment Outcomes
10/31/2023
With drug overdose deaths continuing to climb, Sana Symposium presenter Christopher Nicholas, PhD, said studies suggest that incorporating the use of psychedelics into treatment modalities could improve outcomes.
With drug overdose deaths continuing to climb, Sana Symposium presenter Christopher Nicholas, PhD, said studies suggest that incorporating the use of psychedelics into treatment modalities could improve outcomes.
With drug overdose deaths...
10/31/2023
Psych Congress Network
a caregiver speaks with a doctor
News
Caregivers Confirm Usability of Schizophrenia Cognition Rating Scale
11/14/2024
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
A qualitative study involving...
11/14/2024
Psych Congress Network
Adults Who Smoke Have More Chronic Pain, Use More Opioids
News
Adults Who Smoke Have More Chronic Pain, Use More Opioids
11/07/2024
Rates of chronic pain, prescription opioid use, and severe work limitations rise with the number of cigarettes smoked daily, according to study results published in the American Journal of Preventive Medicine.
Rates of chronic pain, prescription opioid use, and severe work limitations rise with the number of cigarettes smoked daily, according to study results published in the American Journal of Preventive Medicine.
Rates of chronic pain,...
11/07/2024
Psych Congress Network
Patient survey
News
Patient Survey Identifies Barriers to TD Treatment
11/06/2024
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive...
11/06/2024
Psych Congress Network
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
depression stock photo
News
Add-on Lumateperone Eases MDD in Patients With Inadequate Antidepressant Response
11/04/2024
Adjunctive treatment with the atypical antipsychotic lumateperone improved depressive symptoms and severity more than adjunctive placebo in patients with MDD with inadequate response to previous antidepressant therapy, according to a poster...
Adjunctive treatment with the atypical antipsychotic lumateperone improved depressive symptoms and severity more than adjunctive placebo in patients with MDD with inadequate response to previous antidepressant therapy, according to a poster...
Adjunctive treatment with the...
11/04/2024
Psych Congress Network
Conference presenter
News
Olanzapine/Samidorphan Demonstrates Favorable Safety Profile in 4-Year Open-Label Study
11/01/2024
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination...
11/01/2024
Psych Congress Network
A person steps onto a scale
News
Neuropsychiatric Side Effects Reported With CB1 Weight-Loss Drug
10/16/2024
Monlunabant was associated with statistically significant weight loss, but the drug was also linked with mild to moderate neuropsychiatric side effects.
Monlunabant was associated with statistically significant weight loss, but the drug was also linked with mild to moderate neuropsychiatric side effects.
Monlunabant was associated with...
10/16/2024
Psych Congress Network
Increase in Suicidality Associated With FDA Black Box Warning Implementation
News
Increase in Suicidality Associated With FDA Black Box Warning Implementation
10/11/2024
Black box warnings on antidepressants from the FDA warning of increased risk of suicidality were associated with a decline in mental health treatment and an increase in suicide attempts and deaths in young people, according to a systematic...
Black box warnings on antidepressants from the FDA warning of increased risk of suicidality were associated with a decline in mental health treatment and an increase in suicide attempts and deaths in young people, according to a systematic...
Black box warnings on...
10/11/2024
Psych Congress Network
An orange prescription container with generic pills spilling out in front of it
News
Masked Taper Plus CBT for Insomnia Effective in Benzodiazepine Discontinuation
10/10/2024
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined...
10/10/2024
Psych Congress Network
Bright Light Therapy Effective for Depressive Disorders, May Improve Treatment Response Time
News
Bright Light Therapy Effective for Depressive Disorders, May Improve Treatment Response Time
10/09/2024
Bright light therapy (BLT) may be an effective adjunctive treatment for non-seasonal depressive disorders and improve response time for the initial treatment, according to results from a recent systematic review and meta-analysis published in...
Bright light therapy (BLT) may be an effective adjunctive treatment for non-seasonal depressive disorders and improve response time for the initial treatment, according to results from a recent systematic review and meta-analysis published in...
Bright light therapy (BLT) may...
10/09/2024
Psych Congress Network

Blogs

Ketamine Shows Promise in Treatment of Mental Health, Chronic Pain, Addiction
Perspectives
Ketamine Shows Promise in Treatment of Mental Health, Chronic Pain, Addiction
04/12/2021
A report published by CDC in August 2020 showed huge increases in mental health issues during the time period April-June 2020 compared with the same time period the previous year. Instances of suicidal conditions increased 200%, anxiety...
A report published by CDC in August 2020 showed huge increases in mental health issues during the time period April-June 2020 compared with the same time period the previous year. Instances of suicidal conditions increased 200%, anxiety...
A report published by CDC in...
04/12/2021
Addiction Professional
Blog
Psychedelics in Group Therapy for HIV Survivors Shows Promising Results
10/02/2020
BLOG: In a recent study, the utilization of psychedelic medicine in group therapy was linked with reduced demoralization among long-term, gay-identified, male HIV survivors—an outcome with larger implications for overall healthcare.
BLOG: In a recent study, the utilization of psychedelic medicine in group therapy was linked with reduced demoralization among long-term, gay-identified, male HIV survivors—an outcome with larger implications for overall healthcare.
BLOG: In a recent study, the...
10/02/2020
Psych Congress Network
Blog
Psych Congress to Bring Psychedelic-Assisted Therapies Into Focus
09/03/2020
BLOG: Psychedelic-assisted therapies, once consigned to the fringes of psychiatric practice, are exploding into the mainstream of psychiatry and will take center stage at a Psych Congress preconference.
BLOG: Psychedelic-assisted therapies, once consigned to the fringes of psychiatric practice, are exploding into the mainstream of psychiatry and will take center stage at a Psych Congress preconference.
BLOG: Psychedelic-assisted...
09/03/2020
Psych Congress Network
Blog
Psychedelics and Wellness: What’s the Connection?
12/17/2019
BLOG: I sat down with Saundra Jain, MA, PsyD, LPC to better understand the connection between wellness and psychedelics.
BLOG: I sat down with Saundra Jain, MA, PsyD, LPC to better understand the connection between wellness and psychedelics.
BLOG: I sat down with Saundra...
12/17/2019
Psych Congress Network
Blog
The Psychedelic Aspect of Esketamine is an Opportunity, Not a Side Effect
05/23/2019
BLOG: Esketamine represents the first psychedelic treatment approved by the FDA for a psychiatric condition.
BLOG: Esketamine represents the first psychedelic treatment approved by the FDA for a psychiatric condition.
BLOG: Esketamine represents the...
05/23/2019
Psych Congress Network
Blog
A Turning Point for Psychedelics?
06/06/2018
BLOG: Michael Pollan, author of The Omnivore’s Dilemma and The Botany of Desire, has turned his spotlight of curiosity onto the subject of psychedelics with his new book How to Change Your Mind.
BLOG: Michael Pollan, author of The Omnivore’s Dilemma and The Botany of Desire, has turned his spotlight of curiosity onto the subject of psychedelics with his new book How to Change Your Mind.
BLOG: Michael Pollan, author of...
06/06/2018
Psych Congress Network
Blog
Depression as Disconnection: New Lessons From Psychedelic Psychotherapy Studies
11/02/2017
BLOG: Recent qualitative studies on subjects treated with psilocybin may begin to help us understand the subjective experience caused by the drug that may lead to its antidepressant effects.
BLOG: Recent qualitative studies on subjects treated with psilocybin may begin to help us understand the subjective experience caused by the drug that may lead to its antidepressant effects.
BLOG: Recent qualitative studies...
11/02/2017
Psych Congress Network
Blog
Psilocybin Studies: A New Ray of Hope for Psychiatry?
12/01/2016
BLOG: These studies were the latest findings showing that psychedelics, erroneously dismissed as mere intoxicants and swept up in the hysteria of the Nixon-era drug wars, could prove to be as important to psychiatry as penicillin was to...
BLOG: These studies were the latest findings showing that psychedelics, erroneously dismissed as mere intoxicants and swept up in the hysteria of the Nixon-era drug wars, could prove to be as important to psychiatry as penicillin was to...
BLOG: These studies were the...
12/01/2016
Psych Congress Network
Blog
Psychedelics: What to Tell Patients Today
08/25/2015
Psychedelic compounds are powerful, and they have great potential to help patients with intractable conditions. Yet any compound with that kind of power also has the potential to harm, and that harm should not be trivialized.
Psychedelic compounds are powerful, and they have great potential to help patients with intractable conditions. Yet any compound with that kind of power also has the potential to harm, and that harm should not be trivialized.
Psychedelic compounds are...
08/25/2015
Psych Congress Network
Blog
How Psychedelics May Be Used to Accelerate Psychotherapy
08/19/2015
Personal reports from treatment subjects are as compelling as the quantitative data.
Personal reports from treatment subjects are as compelling as the quantitative data.
Personal reports from treatment...
08/19/2015
Psych Congress Network
marc agronin md
Blog
Alzheimer Disease Prevention: Part 2
07/29/2024
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
Rakesh Amin, MD.
Blog
Treating Schizophrenia: The Importance of Early Identification and Intervention
06/13/2023
Rakesh Amin, MD, discusses the importance of partnering with patients and caregivers to set treatment goals and the importance of introducing long-acting injectables earlier in the treatment of schizophrenia.
Rakesh Amin, MD, discusses the importance of partnering with patients and caregivers to set treatment goals and the importance of introducing long-acting injectables earlier in the treatment of schizophrenia.
Rakesh Amin, MD, discusses the...
06/13/2023
Psych Congress Network
Marc Agronin, MD.
Blog
Alzheimer Disease Prevention
08/30/2022
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section...
08/30/2022
Psych Congress Network
Ed Jones, PhD
Blog
How Our Clinicians Can Help Fix the US Health Care System
07/28/2022
Ed Jones, PhD, discusses the need for a clinical refocusing that includes broad access to psychosocial solutions and ensuring socially informed clinicians can help underserved communities.
Ed Jones, PhD, discusses the need for a clinical refocusing that includes broad access to psychosocial solutions and ensuring socially informed clinicians can help underserved communities.
Ed Jones, PhD, discusses the...
07/28/2022
Psych Congress Network
Ed Jones, PhD
Perspective
The Universal Behavior Model: A Comprehensive Approach to Integrated Care
07/21/2022
Ed Jones, PhD: "We miss this psychosocial aspect of care today...What is missing?  We need psychotherapists based in primary care, often focused on mundane issues rather than the complexities of diagnosis or treatment."
Ed Jones, PhD: "We miss this psychosocial aspect of care today...What is missing?  We need psychotherapists based in primary care, often focused on mundane issues rather than the complexities of diagnosis or treatment."
Ed Jones, PhD: "We miss this...
07/21/2022
Psych Congress Network
Chan_Khan_Digital Mental Health
Blog
Who will use it? How to Get Digital Mental Health Apps Into the Hands of Patients
04/27/2022
Steven Chan, MD, MBA, and Burhan Ahmed Khan, MD, discuss how to encourage patients to use digital mental health apps.
Steven Chan, MD, MBA, and Burhan Ahmed Khan, MD, discuss how to encourage patients to use digital mental health apps.
Steven Chan, MD, MBA, and Burhan...
04/27/2022
Psychiatry & Behavioral Health
Chan_Khan_Digital Mental Health
Blog
How to Navigate Quality Issues With Mental Health Apps
04/21/2022
Steven Chan, MD, MBA, and Burhan Ahmed Khan, MD, navigating quality issues with digital mental health applications.
Steven Chan, MD, MBA, and Burhan Ahmed Khan, MD, navigating quality issues with digital mental health applications.
Steven Chan, MD, MBA, and Burhan...
04/21/2022
Psychiatry & Behavioral Health
Andrew Penn, RN, MS, NP, CNS, APRN-BC
Blog
How New NPs Can Find Mentors
03/04/2022
Andrew Penn, NP, explains mentoring, how to find one as an NP, and what to do when you have found a possible mentor. He gives practical advice, questions to ask, and avenues to find the right fit.
Andrew Penn, NP, explains mentoring, how to find one as an NP, and what to do when you have found a possible mentor. He gives practical advice, questions to ask, and avenues to find the right fit.
Andrew Penn, NP, explains...
03/04/2022
Psych Congress Network
Julie Bailey
Blog
How to Be a Safe Space for Someone
02/08/2022
In this blog, Julie Bailey, LCPC, shares her insights on providing a safe space for patients to discuss these social anxieties, as well as tips to share with patients about slowly reintegrating into life after COVID-19.
In this blog, Julie Bailey, LCPC, shares her insights on providing a safe space for patients to discuss these social anxieties, as well as tips to share with patients about slowly reintegrating into life after COVID-19.
In this blog, Julie Bailey,...
02/08/2022
Psych Congress Network
major depressive disorder
Blog
The Best and Worst Changes Brought On By the Pandemic
01/31/2022
Mental health advocate, Dorothy Watson shares her insights about the impact the pandemic has had on mental health and where we go from here.
Mental health advocate, Dorothy Watson shares her insights about the impact the pandemic has had on mental health and where we go from here.
Mental health advocate, Dorothy...
01/31/2022
Psych Congress Network

Interactive Features

Quiz
Quiz: Psilocybin Named Breakthrough Therapy for Which Condition?
12/10/2019
The US Food and Drug Administration (FDA) recently gave the Breakthrough Therapy designation to psilocybin for the treatment of which mental health condition?
The US Food and Drug Administration (FDA) recently gave the Breakthrough Therapy designation to psilocybin for the treatment of which mental health condition?
The US Food and Drug...
12/10/2019
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Expert Insights Quiz
LAIs and Telehealth Psychiatric Care
10/24/2024
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
10/24/2024
Psych Congress Network
Four people ponder with question marks over their heads
Quiz
Adult ADHD Diagnosis Rates
10/23/2024
Take the quiz to test your knowledge!
Take the quiz to test your knowledge!
Take the quiz to test your...
10/23/2024
Psych Congress Network
Jonathan Meyer
Quiz
How do muscarinic acetylcholine receptor activators differ from traditional antipsychotic treatments?
10/23/2024
How do muscarinic acetylcholine receptor activators differ from traditional antipsychotic treatments? Take the quiz to find out!
How do muscarinic acetylcholine receptor activators differ from traditional antipsychotic treatments? Take the quiz to find out!
How do muscarinic acetylcholine...
10/23/2024
Psych Congress NP Institute
pop quiz
Quiz
Esketamine Dosing Schedule for Treatment-Resistant Depression
10/01/2024
During the induction and maintenance phases of esketamine treatment, how frequently should the medication be administered to treat TRD? Take the quiz to test your psychopharmacology knowledge.
During the induction and maintenance phases of esketamine treatment, how frequently should the medication be administered to treat TRD? Take the quiz to test your psychopharmacology knowledge.
During the induction and...
10/01/2024
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
Telehealth Versus In-Person Psychiatric Care
09/19/2024
Do you know what the data from randomized control trials say?
Do you know what the data from randomized control trials say?
Do you know what the data from...
09/19/2024
Psych Congress Network
How many ADHD prescriptions are affected by the med shortage?
Quiz
How many ADHD prescriptions are affected by the med shortage?
09/17/2024
Take a quick poll on your recent prescribing practices!
Take a quick poll on your recent prescribing practices!
Take a quick poll on your recent...
09/17/2024
Psych Congress Network
Symptom Reduction in Bipolar Disorder Treatment
Expert Insights Quiz
Symptom Reduction in Bipolar Disorder Treatment
09/13/2024
Test your knowledge
Test your knowledge
Test your knowledge
09/13/2024
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
CDC/AAP Treatment Guidelines for Pediatric ADHD
09/11/2024
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
09/11/2024
Psych Congress Network
A person completes a puzzle of a profile of a head, with a piece missing from where the brain is located.
Quiz
Considerations When Prescribing Deutetrabenazine for Tardive Dyskinesia
09/10/2024
Put your clinical knowledge to the test with this quiz!
Put your clinical knowledge to the test with this quiz!
Put your clinical knowledge to...
09/10/2024
Psych Congress Network
A person completes a puzzle of a profile of a head, with a piece missing from where the brain is located.
Quiz
Considerations When Prescribing Deutetrabenazine for Tardive Dyskinesia
09/10/2024
Put your clinical knowledge to the test with this quiz!
Put your clinical knowledge to the test with this quiz!
Put your clinical knowledge to...
09/10/2024
Psych Congress Network

Posters

Viloxazine ER (Qelbree®) Administered with Psychostimulants in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Topline Results of a Phase IV Safety Trial
Results of a phase IV, open-label safety study evaluating viloxazine ER (Qelbree®) administered with psychostimulants in pediatric (6-17 years) ADHD; morning vs. evening administration of...
10/26/2023
Withdrawal Catatonia: A Rare Case of Treatment-Resistant Catatonia Secondary to Quetiapine Withdrawal
Catatonia is a psychomotor syndrome with well-defined clinical characteristics, although the neurological mechanisms involved remain unknown. In this study, we report a case of a patient ...
10/26/2023
Zuranolone Safety and Tolerability in Adults with Postpartum Depression: Analyses from SKYLARK, a 50 mg Placebo-Controlled Study
In the SKYLARK Study, zuranolone 50 mg was generally well tolerated in adults with postpartum depression; treatment-emergent adverse events (TEAEs) led to zuranolone dose reduction and di...
10/26/2023
Utilization of Psychiatric Pharmacogenomic Testing by Primary Care Physicians and Advanced Practice Providers: Confidence and Implementation Barriers
Routine implementation of pharmacogenomic testing for mental health and other conditions treated in primary care may require overcoming barriers such as cost to the patient and knowledge ...
10/26/2023
Valbenazine Improves Tardive Dyskinesia With or Without Concomitant Antipsychotic Therapy: A Meta-Analysis of Three Long-Term Valbenazine Trials
Valbenazine is indicated for once-daily treatment of tardive dyskinesia (TD), a movement disorder associated with prolonged antipsychotic exposure. Data from 3 long-term studies (KINECT™-...
10/26/2023
Veterans’ Intensive​ PCMHI Boot Camp​ (VIP Boot Camp)
Veterans Intensive Primary Care Mental Health Integration Bootcamp (VIP Bootcamp): An upstream solution to Mental Health(MH) access issues within the VA system
10/26/2023
Understanding the Real-World Prescription Patterns and Impact of Atypical Antipsychotic Augmentation Timing on Healthcare Cost in Adult Major Depressive Disorder in the United States: A Systematic Literature Review
This study examined the utilization pattern of augmentation with atypical antipsychotics after partial or no response to antidepressants in patients with MDD. The antidepressant prescript...
10/26/2023
Unique Features of the Rapid Mood Screener Enable Detection of Bipolar I Disorder in a Primary Care Practice
The Rapid Mood Screener (RMS) is a self-administered screening tool to help differentiate bipolar I disorder from major depressive disorder. Cases were identified from a primary care sett...
10/26/2023
Use Of VMAT2 Inhibitors For Tardive Dyskinesia In Geriatric Populations - A Case Study
This case report discusses the safety and efficacy of VMAT2 inhibitors in treating antipsychotic induced tardive dyskinesia in adults >55 years old. It also highlights the increased ri...
10/26/2023
Using Chess as a Novel Means to Cure Treatment Refractory Catatonia
The subject matter of the poster includes a case report of a patient with treatment refractory catatonia whose condition rapidly improved following a game of chess, one of the patient's k...
10/26/2023

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Sign Up

Psych Congress Network Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use